Foghorn Therapeutics Inc. (FHTX)

NASDAQ: FHTX · IEX Real-Time Price · USD
6.28
+0.21 (3.46%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Company Description

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.

The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome.

The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.

It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.

Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.
Foghorn Therapeutics logo
Country United States
Founded 2015
IPO Date Oct 23, 2020
Industry Biotechnology
Sector Healthcare
Employees 116
CEO Adrian H. B. Gottschalk

Contact Details

Address:
500 Technology Square, Suite 700
Cambridge, Massachusetts 02139
United States
Phone 617-586-3100
Website foghorntx.com

Stock Details

Ticker Symbol FHTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001822462
CUSIP Number 344174107
ISIN Number US3441741077
SIC Code 2834

Key Executives

Name Position
Adrian H. B. Gottschalk President, Chief Executive Officer and Director
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer
Dr. Gerald R. Crabtree M.d. Founder and Member of Scientific Advisory Board
Stephen J. DiPalma Treasurer and Interim Chief Financial Officer
Karin Hellsvik Vice President, Corporate Affairs and Investor Relations
Michael J. LaCascia Chief Legal Officer
Saurabh Sewak Ph.D. Vice President of Corporate Development
Carlos Costa Chief People Officer
Fanny Cavalie Chief Strategy and Business Operations Officer

Latest SEC Filings

Date Type Title
Mar 7, 2024 8-K Current Report
Mar 7, 2024 10-K Annual Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 8-K Current Report
Jan 17, 2024 8-K Current Report
Jan 8, 2024 8-K Current Report
Jan 3, 2024 8-K Current Report
Nov 2, 2023 10-Q Quarterly Report
Nov 2, 2023 8-K Current Report
Sep 8, 2023 8-K Current Report